NCT04423731View on ClinicalTrials.gov

Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)

Active, not recruitingOBSERVATIONAL
Enrollment

251

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

October 31, 2022

Study Completion Date

December 31, 2025

Conditions
Locally Advanced Pancreatic AdenocarcinomaChemotherapy EffectBorderline Resectable Pancreatic AdenocarcinomaPancreatectomy
Interventions
DRUG

Folfirinox

Neoadjuvant chemotherapy is given according to different regimens, preferably FOLFIRINOX according to the recommendations in the national Norwegian guidelines. The choice of chemotherapy regimen is decided by the treating oncologist.

Trial Locations (1)

0268

Oslo University Hospital, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER

NCT04423731 - Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2) | Biotech Hunter | Biotech Hunter